Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
收藏DataCite Commons2026-03-26 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012885/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
提供机构：
Vivli
创建时间：
2026-03-26
